ClearSky, dedicated to providing clear diagnosis for the neurodegenerative diseases
LID-Monitor is researched and developed by ClearSky Medical Diagnostics Limited, a spinout company from the University of York in the UK, founded by a group of computer science academics, clinicians and pharma industry veterans from all over the world.
ClearSky is specialised in developing digital technologies for the diagnosis and monitoring of Parkinson’s, Alzheimer’s and a range of other neurodegenerative
conditions. ClearSky tackles complex medical problems like Parkinson’s and dementia with a fresh approach by applying years of research of artificial intelligence in medical applications.
The core technology behind ClearSky’s devices is based on unique biologically-inspired computer algorithms developed in close collaboration with leading medical centres and specialists worldwide.
Our work is clinically led and clinically validated. ClearSky has developed a portfolio of non-invasive devices that provide a safe, quick and objective assessment of patients’ symptoms over the past ten years.
Professor Stephen Smith, Founder of ClearSky
Prof Stephen Smith
ClearSky’s co-founder and director, is currently a Professor in the Department of Electronic Engineering at the University of York, has a BSc in Computer Science, an MSc (by Research) and PhD in Electronic Engineering . His research has always been concerned with the application of computers to problems in healthcare.
Professor Stephen Smith and his research group have been named ‘national lifesaver’ on the MadeAtUni list of the top 100 University researchers in recognition of his research into the diagnosis and treatment of Parkinson’s.
Professor Smith and collaborators from Leeds General Infirmary have developed the LID-Monitor, which have the potential to greatly improve the quality of data medical staff can access when prescribing medication or assessing the progression of Parkinson’s.